Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Email*

Password*

Keep me logged in Forgot your password?

Email*

VIDEX PEDIATRIC PWD for ORAL SOLN

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VIDEX PEDIATRIC PWD for ORAL SOLN to:

Generic Name for VIDEX PEDIATRIC PWD for ORAL SOLN

Didanosine 2g, 4g; pwd for oral soln after reconstitution and dilution.

Legal Classification:

Pharmacological Class for VIDEX PEDIATRIC PWD for ORAL SOLN

Nucleoside analogue (reverse transcriptase inhibitor).

Manufacturer of VIDEX PEDIATRIC PWD for ORAL SOLN

Bristol-Myers Squibb Virology

Indications for VIDEX PEDIATRIC PWD for ORAL SOLN

HIV-1 infection.

Adult dose for VIDEX PEDIATRIC PWD for ORAL SOLN

Take on an empty stomach. <60kg: 125mg twice daily. ≥60kg: 200mg twice daily. If once daily dosing required: <60kg: 250mg. ≥60kg: 400mg. Renal impairment (CrCl 30–59mL/min): <60kg: 150mg once daily or 75mg twice daily; ≥60kg: 200mg once daily or 100mg twice daily; CrCl 10–29mL/min: <60kg:100mg once daily; ≥60kg: 150mg once daily; CrCl <10mL/min or dialysis: <60kg: 75mg once daily; ≥60kg: 100mg once daily.

Children's dosing for VIDEX PEDIATRIC PWD for ORAL SOLN

See literature. Take on empty stomach. <2 weeks: not recommended. 2 weeks–8 months: 100mg/m² twice daily. ≥8 months: 120mg/m² twice daily. Renal impairment: consider reducing dose and/or increasing dosing interval.

Also:

VIDEX EC

Contraindications for VIDEX PEDIATRIC PWD for ORAL SOLN

Concomitant allopurinol or ribavirin.

Warnings/Precautions for VIDEX PEDIATRIC PWD for ORAL SOLN

Suspend if signs or symptoms of pancreatitis (discontinue if confirmed), lactic acidosis, or hepatotoxicity (eg, hepatomegaly or steatosis) occurs. Increased risk of pancreatitis (eg, alcohol abuse, advanced HIV disease, elderly, renal impairment); monitor. Women, obesity, or prolonged nucleoside exposure: increased risk of toxicity. Advanced HIV disease, history of neuropathy, or concomitant neurotoxic drugs: consider reducing dose or discontinuing if peripheral neuropathy occurs. Monitor for non-cirrhotic portal hypertension; discontinue if occurs. Hepatic dysfunction. Hyperuricemia. Do periodic retinal exam. Elderly. Pregnancy (Cat.B); monitor for lactic acidosis if used with stavudine. Nursing mothers: not recommended.

Interactions for VIDEX PEDIATRIC PWD for ORAL SOLN

See Contraindications. Avoid with hydroxyurea and stavudine. Potentiated by ganciclovir, tenofovir (reduce dose of didanosine; monitor). Antagonized by methadone. For pediatric pwd: caution with magnesium- or aluminum-containing antacids. Separate dosing of delavirdine, indinavir, nelfinavir by 1 hour; give drugs affected by gastric pH (eg, ketoconazole, itraconazole) 2 hours prior. May antagonize quinolones, tetracyclines. Give at least 6 hours before or 2 hours after ciprofloxacin. See literature for dosing with concomitant tenofovir.

Adverse Reactions for VIDEX PEDIATRIC PWD for ORAL SOLN

GI disturbances, headache, rash; elevated liver enzymes, amylase, and lipase; pancreatitis, lactic acidosis/hepatomegaly with steatosis, retinal changes, optic neuritis, peripheral neuropathy, hyperuricemia, fat redistribution, immune reconstitution syndrome, non-cirrhotic portal hypertension.

Notes for VIDEX PEDIATRIC PWD for ORAL SOLN

How is VIDEX PEDIATRIC PWD for ORAL SOLN supplied?

EC caps—30; Pediatric pwd (bottles)—120mL, 240mL

Related Disease:

HIV~antivirals

Increased Sudden Cardiac Death Rate Among HIV Patients

May 16, 2012

Patients with HIV/AIDS have a significantly increased risk of sudden cardiac death (SCD).

AIDS Relief Assistance Linked to Greater Decline in Mortality

May 16, 2012

All-cause adult mortality declined more substantially in African countries in which the US President's Emergency Plan for AIDS Relief (PEPFAR) program operated more intensively between 2004 and 2008.

Global Deaths in Children Under 5 Down Since 2000

May 11, 2012

From 2000-2010, there was a decrease in the global burden of death in children younger than 5 years of age.

Infectious Agents Cause About One in Six Cancers Worldwide

May 09, 2012

Globally, nearly two million new cancer cases are caused by infectious agents each year.

Tenofovir Disoproxil Fumarate Doesn't Impact Fetal Growth

May 08, 2012

Maternal use of the anti-HIV drug tenofovir disoproxil fumarate (TDF) does not affect fetal growth but may lead to a delayed effect on infant growth in the first year.